clinical trial · NCT07659782
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Non-Small Cell Lung CancerVS-7375
brief summary
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer
started
Jul 22, 2026
primary completion
Jun 1, 2027
completion
Dec 1, 2028
last updated
Aug 10, 2026
official title
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol